临床试验/NCT02517281

NCT02517281已完成不适用

Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies

Gustave Roussy, Cancer Campus, Grand Paris1 个研究点分布在 1 个国家目标入组 141 人开始时间: 2011年7月12日最近更新: 2026年8月19日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Gustave Roussy, Cancer Campus, Grand Paris
入组人数: 141
试验地点: 1
主要终点: Number of clinical secondary effects bind to targeted therapies

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The aim of the study is to do a descriptive analysis of the cutaneous toxicity observed in patients treated using targeted therapies in order to have a better understanding of the skin pathophysiology.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Other
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients with cancer beginning a targeted therapy
•Patients able to follow the protocol
•Age >/= 18 years old
•Signed inform consent

排除标准

•Patient unable to follow the protocol, having a non cooperative behavior or unable to come to follow up visits or unable to complete the study
•Pregnant or breastfeeding woman

研究组 & 干预措施

Patients having received targeted therapies

Experimental

Patients treated using targeted therapies

干预措施: Biopsy (Procedure)

结局指标

主要结局

Number of clinical secondary effects bind to targeted therapies

时间窗: Every 28 days up to 5 years

Dermatological exam including questionnaire, clinical examination and photographies

次要结局

未报告次要终点

研究者

发起方

Gustave Roussy, Cancer Campus, Grand Paris

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

1 期

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary SyndromeMycosis FungoidesSézary Syndrome

NCT02822586Virginia Commonwealth University5

已完成

不适用

To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive SkinSkin Care

NCT03172364GlaxoSmithKline122

终止

1 期

Hypertrophic Scar Prevention by Novel Topical Gel ApplicationHypertrophic Scar

NCT03403621Mayo Clinic6

已完成

2 期

A phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in EGFR-mutated advanced non-small cell lung cancernon-small cell lung cancer

JPRN-jRCTs071190015Takayama Koichi41

已完成

2 期

5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial OligometastasesSolid Tumors With Oligometastatic Spread

NCT01761929University Health Network, Toronto138